Key Concepts

  • Electrical therapy is appropriate for unstable patients in whom a dysrhythmia is the cause of symptoms—pacing if the heart rate is slow, countershock with sedation if fast.

  • Any regular new-onset, symptomatic, wide-complex tachycardia should be assumed to be ventricular tachycardia until proven otherwise.

  • Type II second-degree AV block is never a normal variant and implies a conduction block below the AV node. When the conduction ratio is 2:1, a type II block should be assumed until proven otherwise. Pacing should be readily accessible.

  • Any tachycardia exceeding a rate of 225 to 250 beats/min, regardless of the QRS complex morphology, should be considered an accessory pathway syndrome. Nodal blocking agents should be avoided.

  • Irregularity can be difficult to appreciate in tachycardia over 200 beats/min. Atrial fibrillation can be missed if R-R intervals at fast rates are not carefully tracked.

Foundations

Cardiac Cellular Electrophysiology

The term dysrhythmia denotes any abnormality in cardiac rhythm; it is often used interchangeably with the term arrhythmia . Understanding dysrhythmias begins with understanding the normal electrophysiologic function of cardiac cells. Electrophysiology depends on an intact resting membrane potential, largely the result of differential concentrations of Na + and K + on either side of the cell membrane, measuring approximately −90 mV in normal resting nonpacemaker cells. This gradient exists because of the Na + K + exchange pump and concentration-dependent flow of K + out of the cell. The influx of Ca 2+ through passive exchange with Na 2+ also allows for conduction and myofibril contraction ( Fig. 65.1 ).

Fig. 65.1, Flow of various ions across the myocardial cell membrane. The Na + -K + pump exchanges three Na + ions for each two K 2+ ions, generating a net negative flow of 10 mV. The flow of K down the concentration gradient ( dark arrow ) generates another 80 mV of current. The Na + –Ca 2+ exchange adds little to the resting potential. ATPase, Adenosine triphosphatase.

In normal nonpacemaker cells, an electrical stimulus causes the membrane potential to become less negative, termed depolarization. When the membrane potential reaches −70 mV, specialized Na 2+ channels open, causing a rapid influx of positive charge into the cell. This so-called fast channel activity further decreases the membrane potential and is augmented at 30 to 40 mV by a second slow channel that allows Ca 2+ influx. When these channels close, the resting potential is restored by the sodium-potassium pump, an event termed repolarization ( Fig. 65.2 ).

Fig. 65.2, (A) Action potential of a myocardial cell and its relation to ion flow. (B) Action potentials of various myocardial tissues. (C) Action potentials of various pacemaker cells. Note that phase 4 becomes flatter as its location becomes more distal. AN, Atrial-nodal; AV, atrioventricular; BB, bundle branch fascicles; H, His bundle; N, nodal; NH, nodal-His; SA, sinoatrial.

In nonpacemaker cells, depolarization from a second electrical stimulus is not possible when the membrane potential remains more positive than −60 mV, called the effective refractory period ( Fig. 65.3 ). When the membrane potential reaches −60 to −70 mV, some fast channels are capable of responding but impulse propagation is not normal; this is known as the relative refractory period. At a membrane potential of −70 mV or less, fast channels are ready for activity (see Fig. 65.3 ).

Fig. 65.3, Action potential showing various refractory periods.

Pacemaker cells differ from non–impulse-generating cells in that they can spontaneously depolarize via slow Na + influx. Dominant pacemaker cells are present in the sinoatrial (SA) node, but other pacemaker cells exist in the atrioventricular (AV) node, within the His-Purkinje system, and elsewhere. With a failure of normal pacemaking cells, or in the setting of other pathologic conditions such as metabolic derangement or myocardial ischemia, nonpacemaker cells undergo spontaneous depolarization.

Anatomy and Conduction

The SA node is an area of specialized impulse-generating tissue at the junction of the right atrium and the superior vena cava. Its blood supply is from the right coronary artery (RCA) in 55% of patients and left circumflex artery (LCA) in 45%. The normal SA node produces spontaneous depolarization faster than other pacemakers and is usually the dominant pacemaker. In healthy adults, the SA node typically maintains a rate of 60 to 90 beats/min. Hypothermia and vagal stimulation slow the sinus rate, whereas hyperthermia and sympathetic stimulation increase the rate. Low or absent parasympathetic tone—for example, with certain drugs or after heart transplantation—results in a faster sinus rate.

In the absence of normal SA node impulses, other myocardial tissues may assume the role of a pacemaker. The AV node has an intrinsic impulse-generating rate of 45 to 60 beats/min. Infranodal pacemakers within the His bundle, Purkinje system, and bundle branches maintain intrinsic rates ranging from 30 to 45 beats/min. Under pathologic conditions, other atrial and ventricular tissues may pace the heart at varying rates.

Impulses from the SA node are propagated through the atrial tissue to the AV node. Atrial depolarization is characterized by the P wave on the surface electrocardiogram (ECG; Fig. 65.4 ).

Fig. 65.4, Electrical events in the heart related to surface electrocardiogram (ECG) and His bundle electrogram (HBE). The approximate relationship of sinus node discharge is also related to the surface ECG. AH, Atrioventricular nodal conduction time; HV, His-Purkinje conduction; PA, intra-atrial conduction time; SA, sinoatrial; SP, SA conduction time.

The AV node is an area of conduction tissue separating the atria and the ventricles, located in the posterior-inferior region of the interatrial septum. Its blood supply is from a branch of the RCA in 90% of patients (right dominant) and from the LCA in the remaining 10% (left dominant). Transmission of impulses within the AV node is slower than in other parts of the conducting system ( Table 65.1 ) because of a dependence on slow-channel ion influx for membrane depolarization. An accessory pathway refers to conduction tissue outside the AV node that forms an alternative, or bypass, tract between the atria and ventricles. The term preexcitation refers to early ventricular depolarization via an accessory pathway.

TABLE 65.1
Conduction Velocities in Various Heart Tissues
Tissue Velocity (m/s)
Atrium 1000
Atrioventricular node 200
His-Purkinje system 4000
Ventricles 400

On the surface ECG, the time it takes to conduct an impulse through the atria to the ventricles is represented by the PR interval, normally ranging from 0.10 to 0.20 second (see Fig. 65.4 ). Impulses originating in lower atrial tissues or accessory pathways often have a shortened PR interval. PR prolongation is usually a result of nodal or supranodal conduction system disease.

After passing through the AV node, impulses propagate to the His bundle onto the three main bundle branch fascicles—the right bundle branch (RBB), left anterior-superior bundle (LASB), and left posterior-inferior bundle (LPIB). The RBB and LASB are typically supplied by the left anterior descending (LAD) artery, whereas the RCA or LCA may supply the LPIB. After conduction down the three main bundle branches, impulses are delivered to the Purkinje fibers, propagating impulses to myocardial tissues in a swift and orderly fashion, allowing for coordinated ventricular contraction. If an impulse arrives prematurely, it may be conducted abnormally (termed aberrant , associated with bundles that are relatively refractory) or blocked (if the bundles are entirely refractory).

On the ECG, the QRS complex represents ventricular depolarization (see Fig. 65.4 ), normally 0.09 second or less; 0.12 second or longer is abnormal. The T wave corresponds to ventricular repolarization and its duration depends, among other things, on the length of the cardiac cycle. The QT interval represents the total time of ventricular depolarization and repolarization and is altered by inherent physiologic abnormalities, metabolic changes, drugs, or structural changes. This interval is key to assess for QT prolongation in any patient with syncope or ventricular dysrhythmia, given the link to ventricular dysrhythmia recurrence.

Mechanisms of Dysrhythmia Formation

Enhanced automaticity refers to spontaneous depolarization in nonpacemaker cells or depolarization at an abnormally low threshold in pacemaker cells ( Fig. 65.5 ). Classic examples of enhanced automaticity include the idioventricular rhythms of severe hyperkalemia or myocardial ischemia and the atrial or junctional tachycardias (JTs) associated with digoxin toxicity.

Fig. 65.5, (A) Enhanced normal automaticity ( dashed line ) . (B) Abnormal automaticity. TP, Threshold point.

Triggered activity refers to abnormal impulse(s) resulting from afterdepolarizations. Afterdepolarizations are fluctuations in membrane potential that occur as the resting potential is restored. These fluctuations may precipitate another depolarization just before the full resting potential is reached (early afterdepolarizations) or after full resting potential is reached (delayed afterdepolarizations). The classic dysrhythmia associated with early afterdepolarization is acquired torsades de pointes, which typically arises in the setting of a prolonged QT interval and a new metabolic or drug trigger. Delayed afterdepolarizations classically arise in the setting of rapid heart rates and intracellular Ca 2+ overload, as seen with digoxin toxicity or reperfusion therapy for acute myocardial infarction.

Reentry dysrhythmias arise from repetitive conduction of impulses through a self-sustaining circuit ( Fig. 65.6 ). To maintain a reentry circuit, one conduction pathway must have a longer refractory period than the other so that when an impulse exits one limb of the circuit, it may then reenter the other in retrograde fashion. The cycle is then repeated, creating self-sustaining dysrhythmia. Reentry mechanisms are responsible for most regular narrow-complex tachycardias and many ventricular tachycardias (VTs). Treatment is predicated on altering conduction in one or both limbs of the circuit.

Fig. 65.6, Mechanism of reentry.

Classification of Antidysrhythmic Drugs

The four classes of antidysrhythmic medications are categorized according to their electrophysiologic effects ( Box 65.1 ). Class I agents exert their major effects on the fast Na + channels, resulting in membrane stabilization. The subclasses IA, IB, and IC have differing effects on depolarization, repolarization, and conduction. Class II agents are the β-adrenergic antagonists, which depress SA node automaticity, slow AV node conduction, and suppress conduction in ischemic myocardial tissue. Class III agents prolong repolarization and refractory period duration, predominantly via their effects on K + channels. Class IV agents are the Ca 2+ channel blockers, which slow conduction through the AV node and suppress other calcium-dependent dysrhythmias. Other agents important in the emergency treatment of dysrhythmias include magnesium sulfate, digoxin, and adenosine.

BOX 65.1
Classification of Antidysrhythmic Drugs

Class I

Sodium (fast) channel blockers—slow depolarization with varying effects on repolarization. These drugs have membrane-stabilizing effects.

Class IA

  • Moderate slowing of depolarization and conduction; prolong repolarization and action potential duration.

  • Procainamide

  • Quinidine

  • Disopyramide

Class IB

  • Minimally slow depolarization and conduction; shorten repolarization and action potential duration.

  • Lidocaine

  • Phenytoin

  • Tocainide

  • Mexiletine

Class IC

  • Markedly slow depolarization and conduction; prolong repolarization and action potential duration.

  • Flecainide

  • Propafenone (shares properties with class IA agents)

  • Vernakalant (atrial-specific, investigational)

Class II

  • β-Adrenergic blockers

  • Propranolol

  • Esmolol

  • Metoprolol

  • Atenolol

Class III

  • Antifibrillatory agents—prolong action potential duration and refractory period duration with antifibrillatory properties.

  • Bretylium (historical significance)

  • Amiodarone

  • Dofetilide

  • Ibutilide a

    a Shares activity with class I agents.

  • Sotalol b

    b Shares activity with class II agents.

  • Dronedarone

  • Azimilide

Class IV

  • Calcium (slow) channel blockers

  • Verapamil

  • Diltiazem

Miscellaneous

  • Digoxin

  • Magnesium sulfate

  • Adenosine

Class IA Agents

Class IA agents slow conduction through the atria, AV node, and His-Purkinje system and suppress conduction in accessory pathways. As such, they slow both depolarization and repolarization. Class IA agents also exhibit anticholinergic and mild negative inotropic effects.

Procainamide

Procainamide is the only class IA agent commonly used in the emergency treatment of ventricular and supraventricular dysrhythmias, and it can alter normal and accessory pathway conduction. In stable patients, the recommended administration is a rate of 20 to 30 mg/min until the dysrhythmia is terminated, hypotension occurs, or the QRS complex widens (to 50% of the pretreatment width), up to a total dose of 18 to 20 mg/kg (12 mg/kg if congestive heart failure is present). Procainamide triggers hypotension from vasodilatory effects in 5% to 10% of patients and may be associated with or worsened by infusion rate. It is the preferred agent in treating Wolff-Parkinson-White syndrome.

Class IB Agents

Class IB agents slow conduction and depolarization less than other class I agents, and they shorten repolarization rather than prolonging it. Class IB agents have little effect on accessory pathway conduction.

Lidocaine

Lidocaine is the sole class IB agent used in emergency rhythm management. Lidocaine can suppress dysrhythmias from enhanced automaticity, such as VT. Lidocaine also suppresses SA and AV node function and is associated with asystole in the setting of acute myocardial ischemia. Lidocaine is an alternative to amiodarone but has no efficacy in SVT.

Class IC Agents

The class IC agents profoundly slow depolarization and conduction. More than any other class, these agents are associated with prodysrhythmia , the creation of a new dysrhythmia; this potential new dysrhythmic event also exists with class IA agents albeit much less than class IC. Class IC agents are approved for oral use in the United States.

Flecainide

Flecainide is a class 1C antidysrhythmic agent used for paroxysmal supraventricular tachycardia and certain forms of VT. Flecainide has high oral bioavailability, variable half-life, and narrow therapeutic index, all hampering its use. Flecainide is not recommended for patients with ischemic or structural heart disease.

Propafenone

Propafenone shares electrophysiologic properties with classes IA and IC agents and possesses some β-adrenergic and calcium channel-blocking properties. Oral propafenone is used to prevent atrial fibrillation and ventricular dysrhythmias. Like flecainide, propafenone is used with caution in patients who have ischemic or structural heart disease.

Class II Agents

Class II agents—β-adrenergic blockers—suppress SA node automaticity and slow conduction through the AV node. Because of their effect on AV node conduction, class II agents are well suited to control the ventricular rate in patients with atrial tachydysrhythmias and can be useful to terminate AV nodal reentrant tachycardias (AVNRTs). In the setting of acute myocardial ischemia, beta blockers may lessen the frequency of ventricular dysrhythmias.

All beta blockers are active at β 1 and β 2 receptors ( Table 65.2 ) to varying degrees; those with more prominent β 1 effects are called cardioselective. Relative contraindications to the use of beta blockers include advanced congestive heart failure and third-trimester pregnancy. Historically, beta blockers have been avoided in patients with asthma and chronic obstructive pulmonary disease. However, cardioselective beta blockers are not associated with an increased risk of asthma or chronic obstructive pulmonary disease (COPD) exacerbations. Beta blockers should not be used in patients with preexisting bradycardia or heart block beyond first-degree. Acute side effects of beta blockers include heart failure, excessive bradycardia, and hypotension. In rare cases, they may cause bronchospasm, but most instances are not clinically apparent. Intravenous (IV) beta blockers can trigger additive side effects when used in conjunction with calcium channel blockers, notably hypotension or bradycardia. Only two beta blockers are commonly used in emergency care of dysrhythmias.

TABLE 65.2
Cardiac and Respiratory β-Adrenergic Receptors and Responses to Pharmacologic Manipulation
Response to Receptors Location Stimulation Antagonism
β 1 -Adrenergic Heart Increased heart rate and ectopy Decreased heart rate and ectopy
Increased contractility Decreased contractility
β 2 -Adrenergic Airway (smooth muscle) Decreased tone (relaxation) Increased tone (contraction)
Peripheral vasculature Decreased tone (relaxation) Increased tone (contraction)

Esmolol

Esmolol is an intravenous β 1 -selective agent useful in the emergency setting because of its rapid onset of action and short elimination half-life (minutes). Common dosing of esmolol is an IV bolus of 500 μg/kg followed by a continuous infusion beginning at 50 μg/kg/min and titrating to need and effect.

Metoprolol

Metoprolol is available in oral and IV preparations. Although not approved for dysrhythmia treatment in the United States, metoprolol (5 to 10 mg IV every 10 to 15 minutes in an adult, titrated to response) will slow atrial and nodal tachycardias.

Class III Agents

All class III agents prolong the refractory period primarily by blocking K + channels, with variable effects on the QT interval. In general, class III agents are alternatives to class I agents for the treatment of many ventricular and atrial dysrhythmias.

Amiodarone

Amiodarone is approved for the treatment of ventricular and supraventricular dysrhythmias and is a first line drug treatment for acute ventricular tachycardia. In addition to features in common with all class III agents, amiodarone has other effects, including actions similar to those of class IA, II, and IV agents.

The serum half-life of amiodarone is 9 to 36 days after a single IV dose and up to 107 days during long-term oral use. Because of its unusual pharmacokinetics, oral regimens vary widely. The acute side effects of amiodarone include hypotension, bradycardia, and heart failure ( Box 65.2 ). There is an additive risk of bradycardia and hypotension when amiodarone is used in conjunction with calcium channel or β-adrenergic blockers. Rates of prodysrhythmia are relatively low. Long-term amiodarone use may create extracardiac side effects, including both reversible and irreversible lung and thyroid disease. Amiodarone alters the pharmacokinetics of numerous other drugs, including digoxin and warfarin.

BOX 65.2
Adverse Effects of Amiodarone

Acute Effects

  • Hypotension

  • Slowing of heart rate

  • Decreased contractility

Long-Term Effects

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here